Statistical analysis of REACH trial patients i... - CLL Support

CLL Support

23,336 members40,042 posts

Statistical analysis of REACH trial patients identifies Progression Free Survival prognostic factor for FCR patients

AussieNeil profile image
AussieNeilPartnerAdministrator
2 Replies

Why is this news about FCR - an 'old' immunochemotherapy treatment, so important now that we have non-chemotherapy treatments like Ibrutinib and Idelalisib? Many CLL specialists recognise that for some CLL patients, FCR may be a better choice. Just 6 month's treatment and they can hopefully forget about their CLL for many years, perhaps forever!

REACH (NCT0090051) was an open-label randomized (1:1) phase III trial in relapsed CLL comparing FC with FCR, (that is comparing traditional chemotherapy using Fludarabine+Cyclophosphamide, compared to immunochemotherapy in which the monoclonal CD20 antibody Rituximab/Mabthera is added to the Fludarabine+Cyclophosphamide.) As we now know, FCR was demonstrated to significantly prolong Progression Free Survival (PFS) and most importantly Overall Survival (OS) compared with FC alone in untreated (first-line) patients as well as to improve PFS in previously treated (second-line) patients. FCR is considered the gold standard treatment for CLL, with some patients with the 'right' CLL genetic markers having a PFS in excess of 10 years and considered possibly cured.

Statistical analysis of patients enrolled in REACH has identified INPP5F expression as a prognostic factor for PFS, regardless of adjusting for treatment, age, Binet stage, IGVH mutational status, del(17p) and ECOG performance status. The researchers suggest that INPP5F may serve as a novel, easy-to-assess future prognostic biomarker for fludarabine-based therapy in CLL and "In addition, our data may also support the strategy of combining NF-κB and/or BCL-2 inhibitors to standard therapy in CLL."

More: nature.com/bcj/journal/v5/n...

Neil

Photo: Red rumped parrots on the back lawn

Written by
AussieNeil profile image
AussieNeil
Partner
To view profiles and participate in discussions please or .
Read more about...
2 Replies
dwolden profile image
dwolden

Thank you Neil. When he was recovering from 6 months of FCR, my husband experienced some very grave side effects. Now a year and a half after treatment, we are learning that we have so much to be grateful for. I don't know if he has this prognostic indicator, but his complete response and what we hope will be a long durable remission is thrilling and a blessing for our family. Thank you for this very educational post, I will share it with his oncologist who can now rightly tell me "I told you so."

noeagaman profile image
noeagaman

Thanks for the interesting and reassuring post Neil. I finished four rounds of FCR just over four years ago and have been in remission ever since. My blood counts are finally recovering except for my IGG's. I get IVIG for that since I keep having serious lung infections. I wonder if they will ever recover? At least I have not had any signs of the CLL reactivating yet. I'm keeping my fingers crossed for a long remission.

Chris

Not what you're looking for?

You may also like...

Health Canada approves Ibrutinib plus Rituximab for First Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Good News for our untreated Canadian members! This latest approval is based on...
AussieNeil profile image
Partner

Chemotherapy vs Ibrutinib for CLL Frontline Treatment - Dr Susan O'Brien. 12 to 24% of FCR patients effectively cured 6 years after FCR

Anyone interested in the pros and cons of chemotherapy vs non-chemotherapy treatment should watch...
AussieNeil profile image
Partner

Measurable residual disease (MRD) status predicts Progression Free Survival (PFS) for patients with Chronic Lymphocytic Leukemia (CLL)

Measurable residual disease (MRD) refers to the presence of disease at low levels not detected...
AussieNeil profile image
Partner

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with CLL

This is an abstract from the Lancet article. There's a fair bit of detail missing regarding the...
Jm954 profile image
Administrator

Breaking news form ASH conference: looks like Ibrutinib May be better than FCR for some patients

#ASH18 #LBA | A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard...
Newchallnge profile image